Monte Rosa Therapeutics, Inc. (GLUE) Revenue History
Monte Rosa Therapeutics, Inc. (GLUE) annual revenue history. Get revenue data in Excel with MarketXLS.
Revenue Data
| Period | Revenue (USD) |
|---|---|
| 2021-12-31 | N/A |
| 2022-12-31 | N/A |
| 2023-12-31 | N/A |
| 2024-12-31 | $75.62M |
| 2025-12-31 | $123.67M |
How GLUE compares with sector peers
| Symbol | Company | Revenue (latest fiscal year) |
|---|---|---|
| NTLA | Intellia Therapeutics Inc. | $67.67M |
| ENTA | Enanta Pharmaceuticals Inc. | $65.32M |
| NKTR | Nektar Therapeutics | $55.23M |
| OCUL | Ocular Therapeutix Inc. | $51.95M |
| GOSS | Gossamer Bio Inc. | $48.47M |
These are five companies in the same sector as GLUE with a comparable annual revenue. Each figure above is that company's most recent completed fiscal year, read from the same annual statements as the table on its own page, so the period end dates can differ between rows.
Get Monte Rosa Therapeutics, Inc. Data in Excel
Stream real-time stock prices and financials directly into your spreadsheets with MarketXLS.
Try: =hf_Revenue("GLUE", 2024)
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Volume |
| 2 | GLUE | $11.77 | +0.43% | 0.80M |
| 3 | ||||
| 4 | ||||
| 5 |